The company highlighted its progress in the belapectin development program, which targets galectin-3, a protein involved in fibrosis and inflammation associated with metabolic dysfunction-associated steatohepatitis (MASH) and portal hypertension. CEO Joel Lewis expressed optimism about the program's future, noting that they secured an additional $10 million line of credit from Chairman Dick Uihlein, extending their cash runway through April 2027. This financial maneuver is expected to support ongoing operations and research initiatives.
Galectin Therapeutics also announced that multiple abstracts from the NAVIGATE program have been accepted for presentations at the upcoming EASL Congress, indicating continued interest from the scientific community. The company is preparing for an FDA meeting in the second quarter of 2026 to discuss the next steps for advancing the belapectin program, which aims to address a significant unmet medical need in patients with MASH cirrhosis.
Overall, while the financial results indicate a continued loss, the strategic moves and advancements in clinical trials suggest a positive outlook for Galectin Therapeutics, potentially leading to a favorable impact on its stock price in the near future.
